Journal Title:
Curr Drug Targets
Original Publication Date:
Monday, May 2, 2016
Survival rate using antithymocyte globulins and cyclosporine in patients with aplastic anemia now ranges 70-80%. However, patients with aplastic anemia are faced with significant problems, on the long-term. These long-term issues can be broadly divided on three topics; cyclosporine dependence, relapse of the original disease, and evolution of aplastic anemia to a malignant clonal disease. These long-term issues are briefly reviewed here as well as recent data on the use of next generation sequencing.
Bone Marrow Disease(s):
- aplastic anemia